Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amid Uncertainties, Acorda Preps For Next Phase Of ACA: An Interview With Managed Markets Head Kent Rogers

Executive Summary

With nine months to go before key aspects of the Affordable Care Act are implemented, Acorda Therapeutics’ head of managed markets, Kent Rogers, says he, like everyone, is ‘learning.” Acorda expects to have a game plan ready by mid-summer on how it will adapt its commercial strategy to ACA-initiated changes. Rogers also points out that the company may be less affected than others in the near term because Medicare already covers the majority of patients who take its multiple sclerosis drug Ampyra.

Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055241

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel